Posted On: 07/02/2014 2:02:38 PM
Post# of 777
STEM: StemCells initiated with a Market Outperform at Brinson Patrick; tgt $7 - 7/2/14
Brinson Patrick initiates STEM with a Market Outperform and price target of $7. Firm notes STEM recently reported positive clinical data from the first human neural stem cell transplantation in chronic spinal cord injury (SCI) and geographic atrophy age-related macular degeneration (GA-AMD) with its proprietary HuCNS-SC cells. They expect both indications to generate a robust set of controlled Phase II data over the next 24 months.
Brinson Patrick initiates STEM with a Market Outperform and price target of $7. Firm notes STEM recently reported positive clinical data from the first human neural stem cell transplantation in chronic spinal cord injury (SCI) and geographic atrophy age-related macular degeneration (GA-AMD) with its proprietary HuCNS-SC cells. They expect both indications to generate a robust set of controlled Phase II data over the next 24 months.
(0)
(0)
